One of the gene variants highlighted in the study, called HSD17B4, has already been suggested as a potential drug target in breast cancer, he added. Editor's note: This article was updated on Nov ...

aDepartment of Pharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan bDepartment of Glocal Healthcare Science, Faculty of Pharmaceutical ...

HSD17B4: This gene encodes an enzyme that plays a role in the metabolism of androgens, including testosterone. Variations in the HSD17B4 gene have been associated with an increased risk of BPH.

Our previous studies have proved that 17β-hydroxysteroid dehydrogenase 4 (HSD17B4) is a novel proliferation-promoting protein. The overexpression of HSD17B4 promotes hepatocellular carcinoma (HCC) ...

Certain genetic alterations in circulating tumor cells (CTCs) were associated with treatment outcomes with the androgen receptor (AR) inhibitors enzalutamide (Xtandi) and abiraterone acetate (Zytiga) ...

Gains of ATM, NCOR2, and HSD17B4 were associated with sensitivity to AR inhibitors, while gains of BRCA2, APC, KDM5D, CYP11B1, and SPARC, and losses of CHD1, PHLPP1, ERG, ZFHX3, and NCOR2 were ...

Steroidogenic enzymes are crucial in prostate cancer (PCa) progression. 17β-Hydroxysteroid dehydrogenase type 4 (HSD17B4), encoded by HSD17B4, lacks catalytic capacity in androgen metabolism. Now the ...

Through Oncomine, Human Protein Atlas (HPA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), three K-DEPGs (HSD17B4, ACAA1, and PXMP4) were confirmed to be down-regulated in NSCLC at both ...

对生物统计学复习过程做一个笔记，主要以2015年至2018年考试真题为主，并没有写很多描述性的结论 ...

17β-Hydroxysteroid dehydrogenase type 4 (17βHSD4), encoded by HSD17B4, is thought to inactivate testosterone and dihydrotestosterone by converting them to their respective inert 17-keto steroids.